Abstract
A conformational changing aptamer based electrochemical sensor was developed for the detection of soluble KIT, a cancer biomarker, in human serum. The sensor was fabricated with a ferrocene labeled aptamer (Kd < 5 nM) conjugated to a gold electrode. Quantitative KIT detection was performed using electrochemical impedance spectroscopy (EIS) and square wave voltammetry (SWV). The experimental parameters such as the ratio of aptamer to spacer, aptamer immobilization time, pH, and KIT incubation time were optimized by EIS, and the sensing surface was characterized with voltammetry. The assay specificity was investigated using interfering species showing high specificity towards the target protein. The aptasensor exhibited a wide dynamic range from 10 pg/mL to 100 ng/mL in buffer with a detection limit of 1.15 pg/mL. The sensor also exhibited a linear response with increased KIT concentrations spiked in human serum. The applicability of the sensor was successfully demonstrated using cancer cell conditioned media. The proposed aptasensor can be used in continuous or intermittent approach for cancer therapy monitoring and diagnostics (theranostics).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially supported by the National Science Foundation (1621825), the National Institutes of Health (R41DA044905, R01 CA226803, and UL1TR001442), the UCSD Center for Wearable Systems (CWS), Samsung, the Food and Drug Administration (R01 FD006334), and GIST Research Fund. The content is solely the responsibility of the author(s) and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A, no clinical samples. Data from measured cell lines.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos